Table 4.
(A) The Absorption Percentage (AP), The Absorption Rate Constant (KA), and the Apparent Permeability Coefficient (Papp) and the Enhancement Ratio (ER) Were Calculated by in situ Intestinal Perfusion Method (n=3). (B) Pharmacokinetic Parameters After Oral Administration of ILQ (35 mg/kg) or ILQ-SMEDDS (Equivalent Dose) in Mice
| Items A | ILQ Suspension | ILQ-SMEDDS |
|---|---|---|
| AP/% | 10.36 ± 1.06 | 16.45 ± 1.67±1 |
| Ka/h−1 | 0.059 ± 0.009 | 0.079 ± 0.011 |
| Papp ·10−4/h−1· cm−2 | 4.93 ± 0.51 | 10.27 ± 0.92 |
| Items B | ILQ suspension | ILQ-SMEDDS |
| Ke, h−1 | 0.16 ± 0.03 | 0.22 ± 0.02 |
| T1/2, h | 4.48 ± 1.16 | 3.06 ± 0.29 |
| Tmax, h | 0.50 ± 0.0 | 0.67 ± 0.14 |
| Cmax, μg·mL−1 | 0.37 ± 0.12 | 1.17 ± 0.35* |
| AUC0-12, μg·mL−1·h | 0.67 ± 0.11 | 2.63 ± 0.55** |
| Vz/F, L | 257.61 ± 55.49 | 56.31 ± 16.17** |
Notes: *p < 0.05, **p < 0.01.